<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>將其添加為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Celltrion（068270.KS）已與一家全球製藥公司簽署了合同製造協議，供應藥物原料。Celltrion 將在 2027 年至 2029 年期間供應藥物原料，合同價值約為 2949 億韓元，可能擴展至 3754 億韓元。</p>
<p>在今年早些時候，Celltrion 與禮來公司簽署了 CMO 合同，隨着新協議的增加，該公司的累計 CMO 訂單積壓在今年第一季度超過了 1 萬億韓元。Celltrion 表示正在審查國內外的額外製造設施，以確保足夠的基礎設施並支持不斷增長的全球 CDMO 需求。</p>
<p>Celltrion 的股票交易價格為 206,500 韓元，上漲 3.25%。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

CYCN

標普生物技術 ETF - SPDR

LCTX

<p>Celltrion 與一家全球製藥公司簽署了合同製造協議，計劃在 2027 年至 2029 年期間供應藥物原料，合同價值約為 2949 億韓元，可能擴展至 3754 億韓元。該協議增加了 Celltrion 的合同製造訂單積壓，已超過 1 萬億韓元。公司還在探索額外的生產設施，以滿足日益增長的全球需求。Celltrion 的股價上漲了 3.25%，達到 206,500 韓元</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>將其添加為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Celltrion (068270.KS) has signed a contract manufacturing agreement with a global pharmaceutical company for the supply of drug substance. Celltrion will supply drug substance for three years from 2027 through 2029. The contract value is approximately 294.9 billion Korean won and may expand to 375.4 billion won.</p>
<div class="lb-trans"><p>Celltrion（068270.KS）已與一家全球製藥公司簽署了合同製造協議，供應藥物原料。Celltrion 將在 2027 年至 2029 年期間供應藥物原料，合同價值約為 2949 億韓元，可能擴展至 3754 億韓元。</p>
</div><p>Earlier in the current year, Celltrion signed a CMO contract with Eli Lilly, and with the addition of new agreement, the company's cumulative CMO order backlog surpassed 1 trillion won within the first quarter of the year. Celltrion noted that it is reviewing additional manufacturing facilities both domestically and overseas to ensure sufficient infrastructure and support growing global CDMO demand.</p>
<div class="lb-trans"><p>在今年早些時候，Celltrion 與禮來公司簽署了 CMO 合同，隨着新協議的增加，該公司的累計 CMO 訂單積壓在今年第一季度超過了 1 萬億韓元。Celltrion 表示正在審查國內外的額外製造設施，以確保足夠的基礎設施並支持不斷增長的全球 CDMO 需求。</p>
</div><p>Celltrion shares are trading at 2,06,500 won, up 3.25%.</p>
<div class="lb-trans"><p>Celltrion 的股票交易價格為 206,500 韓元，上漲 3.25%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

Celltrion 與一家全球製藥公司達成合同製造協議